Matrix metalloproteinases: potential therapeutic target for diabetic neuropathic pain

Bibliography

• Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-39
   PubMed Web of Science ®Google Scholar
• Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-73
   PubMed Web of Science ®Google Scholar
• Krizkova S, Zitka O, Masarik M, et al. Clinical importance of matrix metalloproteinases. Bratislavske lekarske listy 2011;112:435-40
   PubMedGoogle Scholar
• Xu X, Xiao LI, Xiao P, et al. A glimpse of matrix metalloproteinases in diabetic nephropathy. Curr Med Chem 2014;21:3244-60
   PubMed Web of Science ®Google Scholar
• Dimas G, Iliadis F, Grekas D. Matrix metalloproteinases, atherosclerosis, proteinuria and kidney disease: linkage-based approaches. Hippokratia 2013;17:292-7
   Google Scholar
• Lenglet S, Mach F, Montecucco F. Role of matrix metalloproteinase-8 in atherosclerosis. Mediators Inflamm 2013;2013:659282
   PubMed Web of Science ®Google Scholar
• Berg G, Miksztowicz V, Schreier L. Metalloproteinases in metabolic syndrome. Clinica Chim Acta 2011;412:1731-9
   PubMed Web of Science ®Google Scholar
• Morgunova E, Tuuttila A, Bergmann U, et al. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science 1999;284:1667-70
   PubMed Web of Science ®Google Scholar
• Jacob-Ferreira AL, Schulz R. Activation of intracellular matrix metalloproteinase-2 by reactive oxygen–nitrogen species: consequences and therapeutic strategies in the heart. Arch Biochem Biophys 2013;540:82-93
   PubMed Web of Science ®Google Scholar
• Evrosimovska B, Velickovski B, Dimova C, Veleska-Stefkovska D. Matrix metalloproteinases (with accent to collagenases). J Cell and Anim Biol 2011;5:113-20
   Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74
   PubMed Web of Science ®Google Scholar
• Birkedal-Hansen H. Matrix metalloproteinases. Adv Dent Res 1995;9:16
   Google Scholar
• Zitka O, Kukacka J, Krizkova S, et al. Matrix metalloproteinases. Curr Med Chem 2010;17:3751-68
   PubMed Web of Science ®Google Scholar
• Massova I, Kotra LP, Fridman R, Mobashery S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 1998;12:1075-95
   PubMed Web of Science ®Google Scholar
• Ganea E, Trifan M, Laslo AC, et al. Matrix metalloproteinases: useful and deleterious. Biochem Soc Trans 2007;35:689-91
   PubMed Web of Science ®Google Scholar
• Mandal M, Mandal A, Das S, et al. Clinical implications of matrix metalloproteinases. Mol Cell Biochem 2003;252:305-29
   PubMed Web of Science ®Google Scholar
• Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD. Matrix metalloproteinases and diabetic vascular complications. Angiology 2005;56:173-89
   Google Scholar
• Roy R, Zhang B, Moses MA. Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res 2006;312:608-22
   PubMed Web of Science ®Google Scholar
• Santos JM, Tewari S, Lin JY, Kowluru RA. Interrelationship between activation of matrix metalloproteinases and mitochondrial dysfunction in the development of diabetic retinopathy. Biochem Biophys Res Commun 2013;438:760-4
   PubMed Web of Science ®Google Scholar
• Mohammad G, Kowluru RA. Novel role of mitochondrial matrix metalloproteinase-2 in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci 2011;52:3832-41
   PubMed Web of Science ®Google Scholar
• Nelson KK, Melendez JA. Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med 2004;37:768-84
   PubMed Web of Science ®Google Scholar
• Zhang H, Chang M, Hansen CN, et al. Role of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury. Neurother 2011;8:206-20
   Google Scholar
• Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15:61-75
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Chattopadhyay S, Kato K, et al. MMPs initiate Schwann cell-mediated MBP degradation and mechanical nociception after nerve damage. Mol Cell Neurosci 2008;39:619-27
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Myers RR, Janes J, Shubayev V. Cytokine regulation of MMP-9 in peripheral glia: implications for pathological processes and pain in injured nerve. Brain Behav Immun 2007;21:561-8
   PubMed Web of Science ®Google Scholar
• Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004;27:1458-86
   PubMed Web of Science ®Google Scholar
• Talbot S, Couture R. Emerging role of microglial kinin B1 receptor in diabetic pain neuropathy. Exp Neurol 2012;234:373-81
   Google Scholar
• Thrailkill KM, Clay Bunn R, Fowlkes JL. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine 2009;35:1-10
   PubMed Web of Science ®Google Scholar
• Singh R, Kishore L, Kaur N. Diabetic peripheral neuropathy: Current perspective and future directions. Pharmacol Res 2014;80C:21-35
   Google Scholar
• Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003;26:1553-79
   PubMed Web of Science ®Google Scholar
• Uemura S, Matsushita H, Li W, et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 2001;88:1291-8
   PubMed Web of Science ®Google Scholar
• Ryan ME, Ramamurthy NS, Sorsa T, Golub LM. MMP-mediated events in diabetes. Ann N Y Acad Sci 1999;878:311-34
   PubMed Web of Science ®Google Scholar
• Frankwich K, Tibble C, Torres-Gonzalez M, et al. Proof of Concept: matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes. J Inflamm (Lond) 2012;9:35
   Google Scholar
• Lakhan SE, Avramut M. Matrix metalloproteinases in neuropathic pain and migraine: friends, enemies, and therapeutic targets. Pain Res Treat 2012;2012:952906
   PubMedGoogle Scholar
• Ji RR, Xu ZZ, Wang X, Lo EH. Matrix metalloprotease regulation of neuropathic pain. Trends Pharmacol Sci 2009;30:336-40
   PubMed Web of Science ®Google Scholar
• Shubayev VI, Myers RR. Upregulation and interaction of TNFalpha and gelatinases A and B in painful peripheral nerve injury. Brain Res 2000;855:83-9
   PubMed Web of Science ®Google Scholar
• Mika J, Zychowska M, Popiolek-Barczyk K, et al. Importance of glial activation in neuropathic pain. Eur J Pharmacol 2013;716:106-19
   PubMed Web of Science ®Google Scholar
• Calvo M, Dawes JM, Bennett DL. The role of the immune system in the generation of neuropathic pain. Lancet Neurol 2012;11:629-42
   PubMed Web of Science ®Google Scholar
• White FA, Jung H, Miller RJ. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci USA 2007;104:20151-8
   PubMed Web of Science ®Google Scholar
• Ji RR, Suter MR. p38 MAPK, microglial signaling, and neuropathic pain. Mol Pain 2007;3:33
   PubMed Web of Science ®Google Scholar
• Kawasaki Y, Xu ZZ, Wang X, et al. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med 2008;14:331-6
   PubMed Web of Science ®Google Scholar
• Ji RR, Gereau RWIV, Malcangio M, Strichartz GR. MAP kinase and pain. Brain research reviews 2009;60:135-48
   PubMed Web of Science ®Google Scholar
• DeLeo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 2001;90:1-6
   PubMed Web of Science ®Google Scholar
• Zhuang ZY, Gerner P, Woolf CJ, Ji RR. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005;114:149-59
   PubMed Web of Science ®Google Scholar
• Gharagozlian S, Svennevig K, Bangstad HJ, et al. Matrix metalloproteinases in subjects with type 1 diabetes. BMC Clin Pathol 2009;9:7
   PubMedGoogle Scholar